Next Article in Journal
Validated HPLC Method for Concurrent Determination of Antipyrine, Carbamazepine, Furosemide and Phenytoin and its Application in Assessment of Drug Permeability through Caco-2 Cell Monolayers
Previous Article in Journal
Simple and Sensitive Stability-Indicating Ion Chromatography Method for the Determination of Cyclopropylamine in Nevirapine and Moxifloxacin Hydrochloride Drug Substances
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2015). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2013, 81(3), 833-842; https://doi.org/10.3797/scipharm.1212-06 (registering DOI)

Poly-Ingredient Formulation Bresol® Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats

Department of Pharmacology, R&D Center, The Himalaya Drug Company, Makali, Bangalore, Karnataka, India
*
Author to whom correspondence should be addressed.
Received: 6 December 2012 / Accepted: 9 May 2013 / Published: 9 May 2013
Download PDF [663 KB, uploaded 29 September 2016]

Abstract

In the present study, the protective effect of Bresol® – a polyherbal formulation – was evaluated in an experimental model of cigarette smoke (CS)-induced COPD in rats. Ten minutes daily exposure to CS for 7 weeks caused significant elevation of TNF-α (p<0.01) and total protein (p<0.01) in the bronchoalveolar lavage fluid (BALF) of positive untreated control animals, indicating ongoing inflammatory process in the lungs. Further, histopathological findings have confirmed the presence of pathological lesions in the trachea and lungs. Five weeks of post-treatment with Bresol® (250 and 500 mg/kg,p.o.) showed significant and dose-dependent anti-inflammatory effects against CS-induced lung abnormalities by maintaining the TNF-α and total protein levels within the normal range. Additionally, Bresol®-treated animals showed normal cyto-architecture of the trachea and lungs. In conclusion, Bresol® showed dose-dependent protection against CS-induced lung and tracheal injury in rats, which further indicates, Bresol® is a useful healing agent, may help to decelerate the progression of COPD, and reduce the exacerbations in patients.
Keywords: Bresol®; Cigarette smoke-induced lung injury; Bronchitis; Broncheoalveolar lavage fluid; TNF-α Bresol®; Cigarette smoke-induced lung injury; Bronchitis; Broncheoalveolar lavage fluid; TNF-α
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

RAFIQ, M.; VISWANATHA, G.L.; SURYAKANTH, D.A.; AZEEMUDDIN, M.; JAGADEESH, M.; DHANUSH, K.; PATKI, P.S. Poly-Ingredient Formulation Bresol® Ameliorates Experimental Chronic Obstructive Pulmonary Disease (COPD) in Rats. Sci. Pharm. 2013, 81, 833-842.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top